A5003614419- Gut microbiota and health
- Clostridium difficile and Clostridium perfringens research
- Pharmacological Effects of Natural Compounds
- Gastrointestinal motility and disorders
- Botulinum Toxin and Related Neurological Disorders
- Microscopic Colitis
- Viral gastroenteritis research and epidemiology
- Probiotics and Fermented Foods
- Nosocomial Infections in ICU
- Complementary and Alternative Medicine Studies
- Cancer Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Bacterial Identification and Susceptibility Testing
- Pancreatitis Pathology and Treatment
- Biosimilars and Bioanalytical Methods
- Science, Research, and Medicine
- Transgenic Plants and Applications
- Metabolomics and Mass Spectrometry Studies
- Colorectal Cancer Treatments and Studies
- Immune Cell Function and Interaction
- Streptococcal Infections and Treatments
- Antibiotic Resistance in Bacteria
- Biotechnology and Related Fields
- Diphtheria, Corynebacterium, and Tetanus
- Chemical Reactions and Isotopes
Vedantra Pharmaceuticals (United States)
2015-2025
PureTech (United States)
2013
Predicting dynamics of host-microbial ecosystems is crucial for the rational design bacteriotherapies. We present MDSINE, a suite algorithms inferring dynamical systems models from microbiome time-series data and predicting temporal behaviors. Using simulated data, we demonstrate that MDSINE significantly outperforms existing inference method. then show MDSINE's utility on two new gnotobiotic mice datasets, investigating infection with Clostridium difficile an immune-modulatory probiotic....
The effect of rationally defined nonpathogenic, nontoxigenic, commensal strains Clostridia on prevention Clostridioides difficile infection (CDI) is unknown.To determine the efficacy VE303, a bacterial consortium 8 Clostridia, in adults at high risk for CDI recurrence. primary objective was to recommended VE303 dosing phase 3 trial.Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study conducted from February 2019 September 2021 27 sites US and Canada. included 79...
Persistent colonization and outgrowth of potentially pathogenic organisms in the intestine can result from long-term antibiotic use or inflammatory conditions, may perpetuate dysregulated immunity tissue damage
Increased levels of proteases, such as trypsin, in the distal intestine have been implicated intestinal pathological conditions1-3. However, players and mechanisms that underlie protease regulation lumen remained unclear. Here we show Paraprevotella strains isolated from faecal microbiome healthy human donors are potent trypsin-degrading commensals. Mechanistically, recruit trypsin to bacterial surface through type IX secretion system-dependent polysaccharide-anchoring proteins promote...
Manipulation of the gut microbiota holds great promise for treatment diseases. However, a major challenge is identification therapeutically potent microbial consortia that colonize host effectively while maximizing immunologic outcome. Here, we propose novel workflow to select optimal immune-inducing from microbiome compositicon and immune effectors measurements. Using published newly generated regulatory T-cell (Treg) data germ-free mice, estimate contributions twelve Clostridia strains...
Abstract Background Repeated antibiotic treatment for recurrent CDI (rCDI) may promote the colonization of antimicrobial resistant (AR) microbes, which can worsen outcomes and increase risk drug-resistant infections. Fecal microbiota products a gut environment to CDI, but these treatments have inherently variable quality attributes, are difficult scale, transfer emerging pathogens. VE303 is defined consortium 8 purified, clonal bacterial strains, overcoming limitations. In CONSORTIUM Study...
Abstract Background Gut microbiota alterations and resulting changes in metabolites involved colonization resistance host responses, including bile acids (BA) short-chain fatty (SCFA), are hallmarks of C. difficile infection. Reduction rCDI was shown with fecal transplants (FMT), but FMT has limitations for routine use carries unforeseen risks. VE303 is a first-in-class drug being developed prevention consisting rationally defined bacterial consortium manufactured under GMP conditions....
<title>Abstract</title> <bold>Persistent colonization and outgrowth of pathogenic organisms in the intestine may occur due to long-term antibiotic usage or inflammatory conditions, which perpetuate dysregulated immunity tissue damage</bold><sup><bold>1,2</bold></sup><bold>. Gram-negative </bold><italic><bold>Enterobacteriaceae</bold></italic><bold> gut pathobionts are particularly recalcitrant conventional treatment</bold><sup><bold>3,4</bold></sup><bold>, though an emerging body evidence...
<h3>Background</h3> The gut microbiome can predict response and adverse events (AEs) in patients with solid tumors receiving anti-programmed cell death protein-1 (anti-PD1) agents like Nivolumab.<sup>1 2</sup> Microbiome modulation fecal microbiota transplantation (FMT) demonstrates the potential of reversing PD-1 resistance melanoma.<sup>3–5</sup> However, FMTs are variable composition, difficult to scale, risk transfer emerging pathogens. VE800 is an 11-strain bacterial consortium made...
Abstract IBD patients can have reduced gut commensal abundance, relative expansion of pro-inflammatory taxa, and microbial diversity short-chain fatty acid production. FMT leads to clinical remission in some UC patients, but is a complex, nonscalable process with inconsistent composition/quality that has led death from transmission pathogens undetected screening. VE202 rationally defined LBP 16 beneficial Clostridia clusters IV, XIVa, XVIII, properties including association healthy human...
Abstract Background: Gut microbiome composition affects response to PD-1 blockade; and recent proof of concept studies suggest that gut manipulation is effective in reversing resistance blockade. VE800 an oral live biotherapeutic consisting 11 distinct non-pathogenic, non-toxigenic, commensal bacterial strains manufactured lyophilized form. induces CD8+ T cell infiltrate into tumors; significantly enhances anti-tumor activity blockade preclinically multiple tumor models a CD103+ dendritic...
in the Journal of Law and Biosciences 1 on regulation fecal microbiota transplants (FMT) brought a welcome hard look at difficulty regulating an area that holds great promise but is often greeted by hoots nervous laughter rather than comprehensive study.FMT has been given relatively little attention legal scholars working food drug law.However, FMT broader field human microbiome 2 have enormous potential for development new therapeutics. 3 Already, shown to greater efficacy treatment...